Cytokinetics, Incorporated (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 10,131 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $14.60, for a total transaction of $147,912.60. Following the transaction, the insider now owns 19,801 shares in the company, valued at $289,094.60. The sale was disclosed in a filing with the SEC, which is available through this link.

Caryn Gordon Mcdowell also recently made the following trade(s):

  • On Tuesday, August 8th, Caryn Gordon Mcdowell sold 11,348 shares of Cytokinetics, stock. The stock was sold at an average price of $12.47, for a total transaction of $141,509.56.

Cytokinetics, Incorporated (NASDAQ CYTK) traded up 1.73% during mid-day trading on Friday, hitting $14.70. 196,159 shares of the stock were exchanged. Cytokinetics, Incorporated has a 12-month low of $8.51 and a 12-month high of $17.20. The firm’s market cap is $788.89 million. The company has a 50 day moving average of $13.52 and a 200 day moving average of $13.37.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.03. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $5.28 million. On average, equities analysts anticipate that Cytokinetics, Incorporated will post ($2.46) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cytokinetics, Incorporated (CYTK) Insider Caryn Gordon Mcdowell Sells 10,131 Shares” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/09/cytokinetics-incorporated-cytk-insider-caryn-gordon-mcdowell-sells-10131-shares.html.

Several institutional investors have recently made changes to their positions in CYTK. Teachers Advisors LLC grew its position in shares of Cytokinetics, by 4.0% during the fourth quarter. Teachers Advisors LLC now owns 53,278 shares of the biopharmaceutical company’s stock worth $647,000 after buying an additional 2,025 shares in the last quarter. Shell Asset Management Co. acquired a new position in shares of Cytokinetics, during the first quarter worth about $551,000. Russell Investments Group Ltd. acquired a new position in shares of Cytokinetics, during the first quarter worth about $2,137,000. Wells Fargo & Company MN grew its position in shares of Cytokinetics, by 46.9% during the first quarter. Wells Fargo & Company MN now owns 39,308 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 12,542 shares in the last quarter. Finally, Capital Fund Management S.A. acquired a new position in shares of Cytokinetics, during the first quarter worth about $213,000. 71.51% of the stock is owned by institutional investors and hedge funds.

CYTK has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Cytokinetics, from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Tuesday, July 11th. ValuEngine upgraded shares of Cytokinetics, from a “sell” rating to a “hold” rating in a report on Friday, September 1st. HC Wainwright set a $26.00 target price on shares of Cytokinetics, and gave the stock a “buy” rating in a report on Thursday, August 3rd. BidaskClub upgraded shares of Cytokinetics, from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Cowen and Company reiterated a “buy” rating and set a $19.00 target price on shares of Cytokinetics, in a report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Cytokinetics, has an average rating of “Buy” and a consensus price target of $21.30.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.